Polyanionic carbosilane dendrimers as a new adjuvant in combination with latency reversal agents for HIV treatment
Abstract Background The major obstacle impeding human immunodeficiency virus-1 (HIV-1) eradication in antiretroviral treatment (ART) treated HIV-1 subjects is the establishment of long-lived latently infected resting CD4+ T cells. Due to the fact that no drug has been effective, the search for new d...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-05-01
|
| Series: | Journal of Nanobiotechnology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12951-019-0500-4 |
| _version_ | 1817996863657213952 |
|---|---|
| author | Ignacio Relaño-Rodríguez Raquel Juárez-Sánchez Carolina Pavicic Eduardo Muñoz Maria Ángeles Muñoz-Fernández |
| author_facet | Ignacio Relaño-Rodríguez Raquel Juárez-Sánchez Carolina Pavicic Eduardo Muñoz Maria Ángeles Muñoz-Fernández |
| author_sort | Ignacio Relaño-Rodríguez |
| collection | DOAJ |
| description | Abstract Background The major obstacle impeding human immunodeficiency virus-1 (HIV-1) eradication in antiretroviral treatment (ART) treated HIV-1 subjects is the establishment of long-lived latently infected resting CD4+ T cells. Due to the fact that no drug has been effective, the search for new drugs and combinations are a priority in the HIV cure. Treatments based on nanotechnology have emerged as an innovative and promising alternative to current and conventional therapies. In this respect, nanotechnology opens up a new door for eliminating latent HIV infection. We studied the role of G1-S4, G2-S16 and G3-S16 polyanionic carbosilane dendrimers in the context of latent HIV-1 persistence. Moreover, we study the efficiency of these dendrimers in combination with latency reversal agents (LRAs) against HIV-1 infection. Methods J89GFP lymphocyte and THP89GFP monocyte derived cell lines latently infected with HIV-1 p89GFP were used as an in vitro model of latency for our study. Viability assays by 3-(4-5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and lactate dehydrogenase (LDH) were performed to determine the working concentrations of dendrimers and LRAs. Both cell lines were treated with G1-S4, G2-S16 and G3-S16 either alone or in combination with bryostatin (BRY), romidepsin (RMD) or panobinostat (PNB) for 24 and 48 h. The expression pattern of GFP was measured by flow cytometry and referred as measure of viral reactivation. Results and discussion The combination treatment of the dendrimers with the protein kinase C (PKC) agonist did not modify the antilatency activity in J89GFP lymphocyte cell line. Interestingly enough, G3-S16 dendrimer alone and its combination with BRY, RMD or PNB showed a significant increased expression of GFP in the THP89GFP monocyte cell line. Conclusion We showed for the first time that nanoparticles, in this case, G3-S16 anionic carbosilan dendrimer may play an important role in new treatments against HIV-1 infection. |
| first_indexed | 2024-04-14T02:29:44Z |
| format | Article |
| id | doaj.art-3dcf834c34b24e52bccda46d3e421ae9 |
| institution | Directory Open Access Journal |
| issn | 1477-3155 |
| language | English |
| last_indexed | 2024-04-14T02:29:44Z |
| publishDate | 2019-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Nanobiotechnology |
| spelling | doaj.art-3dcf834c34b24e52bccda46d3e421ae92022-12-22T02:17:44ZengBMCJournal of Nanobiotechnology1477-31552019-05-011711810.1186/s12951-019-0500-4Polyanionic carbosilane dendrimers as a new adjuvant in combination with latency reversal agents for HIV treatmentIgnacio Relaño-Rodríguez0Raquel Juárez-Sánchez1Carolina Pavicic2Eduardo Muñoz3Maria Ángeles Muñoz-Fernández4Molecular Immunology Laboratory, Hospital General Universitario Gregorio MarañónMolecular Immunology Laboratory, Hospital General Universitario Gregorio MarañónInnohealth, Parque Científico de MadridDepartment of Cell Biology, Physiology and Immunology, Instituto Maimónides de Investigaciones Biomédicas de Córdoba (IMIBIC)/Reina Sofia University Hospital University of CórdobaMolecular Immunology Laboratory, Hospital General Universitario Gregorio MarañónAbstract Background The major obstacle impeding human immunodeficiency virus-1 (HIV-1) eradication in antiretroviral treatment (ART) treated HIV-1 subjects is the establishment of long-lived latently infected resting CD4+ T cells. Due to the fact that no drug has been effective, the search for new drugs and combinations are a priority in the HIV cure. Treatments based on nanotechnology have emerged as an innovative and promising alternative to current and conventional therapies. In this respect, nanotechnology opens up a new door for eliminating latent HIV infection. We studied the role of G1-S4, G2-S16 and G3-S16 polyanionic carbosilane dendrimers in the context of latent HIV-1 persistence. Moreover, we study the efficiency of these dendrimers in combination with latency reversal agents (LRAs) against HIV-1 infection. Methods J89GFP lymphocyte and THP89GFP monocyte derived cell lines latently infected with HIV-1 p89GFP were used as an in vitro model of latency for our study. Viability assays by 3-(4-5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and lactate dehydrogenase (LDH) were performed to determine the working concentrations of dendrimers and LRAs. Both cell lines were treated with G1-S4, G2-S16 and G3-S16 either alone or in combination with bryostatin (BRY), romidepsin (RMD) or panobinostat (PNB) for 24 and 48 h. The expression pattern of GFP was measured by flow cytometry and referred as measure of viral reactivation. Results and discussion The combination treatment of the dendrimers with the protein kinase C (PKC) agonist did not modify the antilatency activity in J89GFP lymphocyte cell line. Interestingly enough, G3-S16 dendrimer alone and its combination with BRY, RMD or PNB showed a significant increased expression of GFP in the THP89GFP monocyte cell line. Conclusion We showed for the first time that nanoparticles, in this case, G3-S16 anionic carbosilan dendrimer may play an important role in new treatments against HIV-1 infection.http://link.springer.com/article/10.1186/s12951-019-0500-4NanomedicineDendrimersHIV-1 latencyLatency reversal agents |
| spellingShingle | Ignacio Relaño-Rodríguez Raquel Juárez-Sánchez Carolina Pavicic Eduardo Muñoz Maria Ángeles Muñoz-Fernández Polyanionic carbosilane dendrimers as a new adjuvant in combination with latency reversal agents for HIV treatment Journal of Nanobiotechnology Nanomedicine Dendrimers HIV-1 latency Latency reversal agents |
| title | Polyanionic carbosilane dendrimers as a new adjuvant in combination with latency reversal agents for HIV treatment |
| title_full | Polyanionic carbosilane dendrimers as a new adjuvant in combination with latency reversal agents for HIV treatment |
| title_fullStr | Polyanionic carbosilane dendrimers as a new adjuvant in combination with latency reversal agents for HIV treatment |
| title_full_unstemmed | Polyanionic carbosilane dendrimers as a new adjuvant in combination with latency reversal agents for HIV treatment |
| title_short | Polyanionic carbosilane dendrimers as a new adjuvant in combination with latency reversal agents for HIV treatment |
| title_sort | polyanionic carbosilane dendrimers as a new adjuvant in combination with latency reversal agents for hiv treatment |
| topic | Nanomedicine Dendrimers HIV-1 latency Latency reversal agents |
| url | http://link.springer.com/article/10.1186/s12951-019-0500-4 |
| work_keys_str_mv | AT ignaciorelanorodriguez polyanioniccarbosilanedendrimersasanewadjuvantincombinationwithlatencyreversalagentsforhivtreatment AT raqueljuarezsanchez polyanioniccarbosilanedendrimersasanewadjuvantincombinationwithlatencyreversalagentsforhivtreatment AT carolinapavicic polyanioniccarbosilanedendrimersasanewadjuvantincombinationwithlatencyreversalagentsforhivtreatment AT eduardomunoz polyanioniccarbosilanedendrimersasanewadjuvantincombinationwithlatencyreversalagentsforhivtreatment AT mariaangelesmunozfernandez polyanioniccarbosilanedendrimersasanewadjuvantincombinationwithlatencyreversalagentsforhivtreatment |